Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Effect of Rosuvastatin on Endothelial Function in Patients With Diabetes and Glaucoma
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Medical University of Vienna
- Registration Number
- NCT00913562
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of Anti-inflammatory Effects
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 20
- Registration Number
- NCT00874757
- Locations
- 🇺🇸
University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska, United States
Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 125
- Registration Number
- NCT00871351
Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level
- Conditions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2009-03-20
- Lead Sponsor
- Ramathibodi Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT00866229
- Locations
- 🇹🇭
Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 808
- Registration Number
- NCT00862251
Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- University of Rome Tor Vergata
- Target Recruit Count
- 30
- Registration Number
- NCT00854503
- Locations
- 🇮🇹
University of Rome Tor Vergata, Rome, Italy
Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?
- Conditions
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2009-10-01
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT00851175
- Locations
- 🇳🇱
RUNMC, Nijmegen, Netherlands
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00826358
- Locations
- 🇺🇸
Site Reference ID/Investigator# 13441, Orlando, Florida, United States
Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
- First Posted Date
- 2008-12-30
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 97
- Registration Number
- NCT00815659
- Locations
- 🇹🇷
Research site, Kocaeli, Umuttepe, Turkey
🇹🇷Research Site, Trabzon, Turkey
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
- First Posted Date
- 2008-12-16
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00808678
- Locations
- 🇺🇸
Site Reference ID/Investigator# 14762, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.